While the linked article focuses on Eli Lilly and Regeneron mabs, in about 5-6 weeks from now, CytoDyn will have it's own headlines. The more light that can be shined on mabs and therapeutics, the better for CYDY. Interestingly, the article says that the earlier a mab can be administered (first 1 to 10 days) the better. How powerful will leronlimab look by being able to be given to a severe/critical patient, probably beyond day 10, and save their life! I hope the FDA doesn't pigeon hole leronlimab to only severe/critical patients. Doctors need complete access to leronlimab for patients with commodities before they become critical!

https://www.cnn.com/2020/12/16/health/monoclo...index.html